Il­lu­mi­na to di­vest Grail, two years af­ter $8B deal was stymied by an­titrust is­sues

Il­lu­mi­na will di­vest its can­cer di­ag­nos­tic sub­sidiary Grail, it an­nounced Sun­day, end­ing a painful years-long saga in which the prized ac­qui­si­tion was held up by an­titrust reg­u­la­tors.

The move fol­lows a mixed de­ci­sion from the U.S. Fifth Cir­cuit Court of Ap­peals on the Fed­er­al Trade Com­mis­sion’s an­titrust case against the deal. Il­lu­mi­na said that rather than con­tin­ue the le­gal fight, which has been an on­go­ing dis­trac­tion for the com­pa­ny, it would sell Grail or spin it out in­to an in­de­pen­dent by the sec­ond quar­ter of 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER